New pill aims to keep deadly leukemia at bay after risky transplant
NCT ID NCT07304232
Summary
This study is testing whether a pill called Chidamide can help prevent a dangerous blood cancer (AML) from coming back after a stem cell transplant. It will involve about 134 patients who are at high risk of the cancer returning. One group will take the pill for up to two years, while another group is observed without the drug, to see if the treatment improves survival and keeps the cancer in remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
The First Affiliated Hospital of Harbin Medical University
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150001, China
Contact
-
The Second Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, 050000, China
Contact
-
Tianjin Medical University General Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact
-
Tianjin People's Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.